Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

Pharmacokinetics of Antistaphylococcal Antibiotics in Infants

Multiple center, open-label, PK study

Pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics in hospitalized infants with suspected systemic infection or receiving one of the study drugs per local standard of care. Number of participants are 16-32 evaluable per each study drug of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics.

Inclusion Criteria:

• Sufficient intravascular access
• Suspected systemic infection or receiving 1 of the study drugs per standard of care
• informed consent from legal guardian

Exclusion Criteria:

• history of allergic reaction to study drugs
• urine output <0.5 mL/hr/kg over the prior 24 hours
• serum creatinine >1.7 mg/dl
• Any condition in investigator judgment precludes participation because it could affect participant safety